FDA warning letter threatens Celltrion's valuable Inflectra franchise

7 February 2018
biosimilars_samples_large

Pfizer’s (NYSE: PFE) manufacturing partner in South Korea Celltrion (Kosdaq: 068270) has received a warning letter from the US Food and Drug Administration after an inspection of its Incheon-based facility uncovered “issues related to certain manufacturing processes.”

The FDA says its inspection in the first part of 2017 revealed “significant violations of current good manufacturing practice (CGMP).”

The firm says it’s “making progress addressing these concerns” and that it will “provide a full response to the FDA within the next 15 days.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars